GSK Announces Major Acquisition of Nuvalent
British pharmaceutical company GSK has announced one of its largest deals under new chief executive Luke Miels, agreeing to acquire US cancer treatment firm Nuvalent for $10.6 billion (£7.9 billion). The acquisition aims to strengthen GSK's oncology portfolio by adding Nuvalent's pipeline of cancer drugs.
Nuvalent, based in Boston, specializes in developing cancer therapies, including three focused on lung cancer. The deal notably includes two late-stage next-generation treatments for non-small cell lung cancer (NSCLC), which are currently under review by the US Food and Drug Administration (FDA). Regulatory decisions on these drugs are expected in September and November of this year.
Details on the Acquired Treatments
The two drugs, zidesamtinib and neladalkib, are anticipated to launch later this year pending FDA approval. Both have the potential to become multi-blockbuster therapies, with projected annual revenues in the billions of dollars. These treatments target specific mutations that drive lung cancer, predominantly affecting non-smoking adults aged 40 to 50, mostly females. The therapies aim to provide longer-lasting effectiveness and improved quality of life through better tolerability.
Strategic Significance and Historical Context
This acquisition marks the largest deal since Luke Miels took over as GSK's CEO earlier this year. It also represents GSK's biggest acquisition to date. Previously, the company's largest transaction was a $21 billion asset swap with Novartis in 2014. That deal involved GSK acquiring Novartis's vaccines division for $5.25 billion while selling its cancer portfolio to Novartis for $16 billion under then-CEO Andrew Witty.
Miels, who formerly served as GSK's chief commercial officer, is continuing the oncology expansion initiated by his predecessor Emma Walmsley in 2017. However, the scale of this latest acquisition has surprised investors, given that GSK had focused on smaller bolt-on acquisitions in recent years.
“Today’s acquisition is a multi-product deal, consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap. The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non-small cell lung cancer.”
Future Growth and Pipeline Prospects
Miels emphasized that the acquisition offers GSK immediate new sales growth opportunities and is expected to improve profit contributions starting in 2027. Additionally, it provides a platform for rapid expansion in lung cancer treatment with a product called Ris-Rez, which is currently in late-stage clinical development.
GSK anticipates that Ris-Rez could treat multiple cancer types and contribute toward the company's goal of exceeding £40 billion in annual sales by 2031.
Additional Developments
Earlier this year, in January, GSK also advanced its pipeline by developing a drug aimed at protecting against severe food allergies, including allergies to nuts, milk, and eggs.
